Clinical Trial Update: BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BGB-A317 in combination with chemotherapy as first-line treatment for adults with inoperable, locally advanced, or metastatic esophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• BGB-A317 (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | Phase 2 | Status: COMPLETED